Homology Medicines Faces Nasdaq Delisting Notice

TL;DR

**FIXX is facing a Nasdaq delisting notice, signaling major trouble for its stock.**

AI Summary

Homology Medicines, Inc. (FIXX) filed an 8-K on January 3, 2024, reporting an event on December 29, 2023, related to a notice of delisting or failure to satisfy a continued listing rule. This filing indicates potential issues with their Nasdaq Global Select Market listing, which could lead to their stock being removed from the exchange. For investors, this matters because delisting often results in decreased liquidity and a lower stock price, making it harder to buy or sell shares.

Why It Matters

This filing signals that Homology Medicines, Inc. is at risk of being delisted from the Nasdaq Global Select Market, which could severely impact the stock's liquidity and investor confidence.

Risk Assessment

Risk Level: high — A delisting notice indicates significant operational or financial issues that could lead to the stock being removed from a major exchange, severely impacting its value and tradability.

Analyst Insight

A smart investor would consider selling shares of Homology Medicines, Inc. (FIXX) to avoid further potential losses due to the high risk of delisting and the associated negative impacts on liquidity and stock value.

Key Players & Entities

• Homology Medicines, Inc. (company) — the registrant facing delisting
• Nasdaq Global Select Market (company) — the exchange from which Homology Medicines, Inc. may be delisted
• December 29, 2023 (date) — date of the earliest event reported regarding the delisting notice
• January 3, 2024 (date) — date the 8-K filing was made
• FIXX (company) — trading symbol for Homology Medicines, Inc.

Forward-Looking Statements

• Homology Medicines, Inc. will likely experience a significant drop in stock price due to reduced investor confidence and liquidity concerns. (Homology Medicines, Inc.) — high confidence, target: Q1 2024
• The company may attempt to appeal the delisting decision or seek a listing on an over-the-counter (OTC) market. (Homology Medicines, Inc.) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FIXX The Nasdaq
• $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued lis
• $5,000 — t. The Company would also need to pay a $5,000 application fee to Nasdaq and to provid

Filing Documents

• d648217d8k.htm (8-K) — 42KB
• d648217dex991.htm (EX-99.1) — 18KB
• g648217g0103223207656.jpg (GRAPHIC) — 4KB
• 0001193125-24-001519.txt ( ) — 195KB
• fixx-20231229.xsd (EX-101.SCH) — 3KB
• fixx-20231229_lab.xml (EX-101.LAB) — 17KB
• fixx-20231229_pre.xml (EX-101.PRE) — 11KB
• d648217d8k_htm.xml (XML) — 3KB

01

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 29, 2023, Homology Medicines, Inc. (the " Company " or " Homology ") received a letter (the " Nasdaq Notification ") from The Nasdaq Stock Market LLC (" Nasdaq ") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the " Minimum Bid Price Requirement "). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until June 26, 2024, to regain compliance with the Minimum Bid Price Requirement. As previously disclosed in the Company's Registration Statement on Form S-4 filed with the Securities and Exchange Commission (the " SEC ") on December 18, 2023, the Company intends to seek stockholder approval for a reverse stock split of its common stock at a special meeting of stockholders to be held in connection with its proposed merger with Q32 Bio Inc. (" Q32 ") and, if approved, effect the reverse stock split immediately prior to the closing of the merger. If, at any time before June 26, 2024, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of ten (10) consecutive business days, the Nasdaq staff will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement. If the Company fails to regain compliance with the Minimum Bid Price Requirement by June 26, 2024, the Company may be eligible for a second 180 calendar day compliance period. To qualify, the Company must submit an application to transfer the listing of its common stock to The Nasdaq Capital Market, which requires the Company to meet the continued listing requirement for the market value of publicly held shares and all other initial listi

01

Item 7.01. Regulation FD Disclosure. On January 3, 2024, the Company issued a press release announcing that it had received the Nasdaq Notification. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report") and is incorporated into this Item 7.01 by reference. The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1. Important Information about the Merger and Where to Find It This Current Report relates to a proposed transaction between Homology and Q32. In connection with the proposed transaction, Homology filed a registration statement on Form S-4 that includes a preliminary proxy statement of Homology and constitutes a prospectus with respect to shares of Homology's common stock to be issued in the proposed transaction (the " Proxy Statement/Prospectus "). Homology may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement/Prospectus or any other document which Homology may file with the SEC. The registration statement has not yet become effective. After the registration statement is effective, the Proxy Statement/Prospectus will be mailed to stockholders of Homology. INVESTORS, Q32 STOCKHOLDERS AND HOMOLOGY STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT ARE OR WILL BE FILED BY HOMOLOGY WITH T

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of the Company dated January 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HOMOLOGY MEDICINES, INC. Date: January 3, 2024 By: /s/ Paul G. Alloway, Ph.D. Name: Paul G. Alloway, Ph.D. Title: President, Chief Operating Officer and Secretary 4

View Full Filing

View this 8-K filing on SEC EDGAR